Sobi publishes 2016 Annual Report
Swedish Orphan Biovitrum AB (publ) (Sobi™) publishes today its 2016 Annual Report. The report summarises the business as well as financial highlights for 2016, and gives a deeper insight into the company’s strategic agenda and its patient-centric innovation model. “We took a major step in 2016 by launching Elocta and Alprolix, two first in class extended half-life Fc fusion clotting factors to people with haemophilia in Europe and in parts of the Middle East. Throughout the year we have come to understand the positive impact that these therapies can bring to